GYRE THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
GYRE THERAPEUTICS INC - PROCEEDS TO ADVANCE PHASE 2 TRIAL OF F351 IN MASH-ASSOCIATED LIVER FIBROSIS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.